BridgeMD
Intra-arterial thrombolysis after SUCCESSful reperfusion of acute ischemic stroke
EU CTIS ID: 2023-506935-14-01
What this study is testing
To demonstrate the superiority of adjunct IA thrombolysis versus no adjunct IA thrombolysis on 90-day functional outcome rate (shift of 90-day modified Rankin Scale [mRS] toward a better functional outcome) in patients with acute anterior circulation LVO stroke who have successful angiographic reperfusion (eTICI 2b-2c-3) after IVT alone, bridging therapy, or MT alone.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- • Pre-stroke mRS 0-2
- • Acute ischemic stroke with anterior circulation LVO defined as intracranial internal carotid artery, M1, or M2 occlusion proven on CT or MRI
- • NIHSS score ≥ 5 at admission
- • eTICI 2b-2c-3 after IVT alone, bridging therapy (IVT + MT), or MT alone and confirmed by catheter angiogram
You likely can't join if
- • Contraindications for IA thrombolysis: Platelet count <100 000/mm3, INR >1.7, AOD use <48h or biological confirmation of activity and effective heparin treatment
- • Intracerebral hemorrhage
- • Occlusion or high grade stenosis treated by stenting
- • Patient expected to be unable to present or be available for 3-month visit follow-up
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.